The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many ...

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

The investment, which the foundation says is its largest in women’s health, will support research in maternal health, ...

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggests big pharma may finally be willing to place ...

The company formerly known a Sosei Heptares unveiled new weight loss programs. Elsewhere, BridgeBio and Madrigal unveiled ...

Frazier was among the most active venture investors in 2024, according to analysts at William Blair, backing 17 private life ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

An executive order President Trump signed Thursday codifies rates for over 60 trading partners, including Switzerland. A ...